1. "Breast Medicine Service"
Formats
  1. Journal Article (2170)
  2. Meeting Abstract (1650)
  3. Review (78)
  4. Book Section (67)
  5. Editorial (42)
  6. Conference Paper (28)
  7. Guidelines (26)
  8. Correspondence (16)
  9. Miscellaneous (11)
  10. Research Letter (10)
  11. Book Whole (5)
Groups
  1. Breast Medicine Service (4103)
  2. Department of Medicine (4103)
  3. Solid Tumor Oncology Division (4103)
  4. Survivorship Research (2337)
  5. GSK Faculty (1492)
  6. Population Sciences Research Program (1339)

More Groups

People
  1. Clifford Hudis (905)
  2. Larry Norton (758)
  3. Mark Robson (676)
  4. Neal Rosen (425)
  5. Andrew Seidman (318)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (57)
  2. 2024 (192)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (802)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (169)
  4. Annals of Oncology (158)
  5. Clinical Cancer Research (128)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (853)
  2. American Association for Cancer Research (749)
  3. Springer (329)
  4. Elsevier Inc. (322)
  5. Oxford University Press (278)
  6. Nature Publishing Group (273)

More Publishers

Results (4103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)
    Meeting Abstract

    George, M.; Frenel, J. S.; CorteĢs, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Meeting Abstract

    Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Losada, M. J. V.; Park, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
    Meeting Abstract

    Modi, S.; Byng, D.; Zhang, S.; Xiong, Y.; Hunter, S.; Struebing, A.; Dunton, K.; Mbanya, Z.; Jacot, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
    Meeting Abstract

    Cabel, L.; An, J. A. R.; Kurtz, D.; Ross, D.; Dikoglu, E.; Chen, Y.; Murphy, K.; Szuhany, K.; Stowell, S. L.; Maloney, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)
    Meeting Abstract

    Jhaveri, K.; Pegram, M.; Neven, P.; Curigliano, G.; Spring, L. M.; Gligorov, J.; Schlam, I.; Harbeck, N.; Juric, D.; Lim, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
    Meeting Abstract

    Page, D. B.; Kaur, L.; Hong, E. C. C.; Su, A.; Moxon, N.; Mellinger, S.; Kelly, T.; Kelley, A.; Fredrich, N.; Seino, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
    Meeting Abstract

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J.; Janni, W.; Jhaveri, K.; Mouabbi, J. A.; Brufsky, A. M.; Hamilton, E. P.; Oregan, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save